钙稳态调节剂1基因P86L多态性与阿尔茨海默病风险：一项荟萃分析。

Calcium homeostasis modulator 1 gene P86L polymorphism and the risk for alzheimer's disease: A meta-analysis.

作者信息

Mun Myung-Jin, Kim Jin-Ho, Choi Ji-Young, Jang Won-Cheoul

机构信息

Department of Chemistry, School of Natural Science, Dankook University, Cheonan 330-714, South Korea; Department of Nanobiomedical Science and BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University Graduate School, South Korea; Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan 330-714, South Korea.

Department of Chemistry, School of Natural Science, Dankook University, Cheonan 330-714, South Korea.

出版信息

Neurosci Lett. 2016 Apr 21;619:8-14. doi: 10.1016/j.neulet.2016.02.049. Epub 2016 Mar 2.

DOI:10.1016/j.neulet.2016.02.049

PMID:26944452

Abstract

OBJECTIVES

Recently, many epidemiological studies have demonstrated an association between P86L polymorphism of calcium homeostasis modulator 1 (CALHM1) and risk for Alzheimer's disease (AD). However, the results of these association studies are inconsistent. In this study, we re-evaluated the relation between CALHM1 P86L polymorphism and risk for AD in a meta-analysis.

METHODS

This meta-analysis was performed using the PubMed, Science Direct, Scopus and Google Scholar databases up to June 2015 using the search terms "CALHM1" and "polymorphism or SNP or variant" in combination with "Alzheimer's disease". A meta-analysis with pooled odds ratios and 95% confidence intervals was carried out to assess the associations between P86L polymorphism and the risks for Alzheimer's disease under four genetic models with fixed or random effects models.

RESULTS

Sixteen studies (twenty-four subgroup studies involving 9795 cases and 15,335 controls) were included in our meta-analysis. Our meta-analysis results indicated that several genetic models of CALHM1 P86L polymorphism were significantly associated with increased risk for AD in overall and Caucasian populations.

CONCLUSIONS

In conclusion, our comprehensive meta-analysis indicated that P86L polymorphism is significantly associated with an increased risk for AD. Our data suggest that CALHM1 polymorphism may be potential biomarker in patients with AD.

摘要

目的

最近，许多流行病学研究已证明钙稳态调节剂1（CALHM1）的P86L多态性与阿尔茨海默病（AD）风险之间存在关联。然而，这些关联研究的结果并不一致。在本研究中，我们通过荟萃分析重新评估了CALHM1 P86L多态性与AD风险之间的关系。

方法

本荟萃分析使用截至2015年6月的PubMed、Science Direct、Scopus和谷歌学术数据库，搜索词为“CALHM1”和“多态性或单核苷酸多态性或变异体”并结合“阿尔茨海默病”。采用固定效应模型或随机效应模型进行荟萃分析，合并比值比和95%置信区间，以评估P86L多态性与阿尔茨海默病风险在四种遗传模型下的关联。